OBI Pharma Signs Collaboration and License Agreement with Novartis

Following Presidential Office Recognition, OBI Pharma Showcases the Strength of Its Obrion® ADC Platform and Accelerates Global Licensing to Capture Expanding Market Opportunities

OBI Pharma’s Obrion® ADC Technology Platform Wins Product Innovation of the Year at the 2026 Taiwan BIO Awards

OBI Holds 2026 Annual Shareholders’ Meeting
Capturing Global Opportunities in Next-Generation ADCs with Its Proprietary Obrion® Platform to Advance Bispecific Dual-Payload ADCs and International Licensing Strategy

OBI Presents Three Featured Talks at the 2026 World ADC Summit South Korea
Highlighting GlycOBI® and Dual-Payload ADC Technologies

OBI Announces US FDA Registration and Activation of HYProtecan™ Type II Drug Master File
Supporting Obrion Engine™ ADC Technologies and Enhancing Regulatory Efficiency

OBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies
Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies.

OBI Presents Obrion™ ADC Technologies at AntibodyChina 2026 in Shanghai
Highlighting Scalable Manufacturing and Bispecific Dual-Payload Design

OBI Participated in BIO-Europe Spring®, Advancing International Business Development
Engaged with Multiple Global Pharma Companies for Licensing Discussions